www.boehringer-ingelheim.com
Evotec and Boehringer Ingelheim Enter into Target Discovery Collaboration in Alzheimer's Disease
A multi-year collaboration with Boehringer Ingelheim to jointly identify novel targets as potential points of intervention in the treatment of Alzheimer's disease (AD). The collaboration will also involve the Research Institute of Molecular Pathology in Vienna (IMP).
Evotec scientists together with the IMP will apply their proprietary and well validated disease models to identify novel AD targets. Based on these models, Boehringer Ingelheim will select and further validate target candidates for its in-house drug discovery program with the goal of developing innovative novel therapeutics.
The contract also includes an option for Evotec to support Boehringer Ingelheim (BI) in the target validation process.
"We are very pleased with the rapid progress achieved in the collaboration. The basis for this second milestone achievement was both the strong interdisciplinary project work as well as the good team spirit between the Boehringer Ingelheim and Evotec scientists. We are looking forward to further progress with the two advanced projects and to further exciting research activities."
Professor Mikael Dolsten, Head of Corporate Division Pharma Research/Discovery, Boehringer Ingelheim GmbH